Status:
ACTIVE_NOT_RECRUITING
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
University of California, San Diego
Conditions:
Obstructive Sleep Apnea
Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebro...
Detailed Description
Hodgkin lymphoma (HL) survivors being following at St. Jude within the SJLIFE protocol cohort who were treated with TRT will be recruited to complete a comprehensive neurocognitive evaluation, overnig...
Eligibility Criteria
Inclusion
- HODGKIN LYMPHOMA SURVIVOR ELIGIBILITY CRITERIA
- Inclusion Criteria (Hodgkin Lymphoma Survivor):
- Current participant in the SJLIFE clinical trial ongoing at St. Jude Children's Research Hospital (SJCRH) and was treated with thoracic radiation for Hodgkin lymphoma
- Currently ≥ 18 years of age
- ≥ 5 years from original diagnosis
- Exclusion Criteria (Hodgkin Lymphoma Survivor):
- History of cranial or total-body radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs
- Currently pregnant
- Secondary central nervous system (CNS) neoplasm
- COMPARISON GROUP (CONTROL) ELIGIBILITY CRITERIA
- Inclusion Criteria (Comparison Group):
- Research participant is a sibling, parent, relative or friend of a current or former St. Jude patient
- Research participant must be at least 18 years of age at the time of the scheduled evaluation
- Exclusion Criteria (Comparison Group):
- History of cranial, total-body or thoracic radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs
- Currently pregnant
- History of cancer
- 1st degree relative of a survivor included in the current study.
Exclusion
Key Trial Info
Start Date :
January 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 10 2028
Estimated Enrollment :
434 Patients enrolled
Trial Details
Trial ID
NCT03361020
Start Date
January 23 2018
End Date
July 10 2028
Last Update
November 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105